secwatch.observer — SEC 8-K summary
======================================

Issuer:     Relay Therapeutics, Inc. (RLAY)
CIK:        0001812364
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0000950170-22-007848
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Relay Therapeutics Q1 net loss $62M ($0.57/shr); cash $898M; RLY-2608 combo arm initiated
--------------------------------------------------------------------------------

- Net loss of $62.0M ($0.57/shr) vs $42.2M ($0.47) in Q1 2021; R&D expenses rose to $51.7M.
- Cash, equivalents and investments $898M (down from $958M at Dec 31, 2021); sufficient into 2025.
- Initiated fulvestrant combination arm of RLY-2608 (pan-mutant PI3Kα inhibitor) dose escalation; initial data expected H1 2023.
- RLY-4008 (FGFR2 inhibitor) received FDA orphan drug designation for cholangiocarcinoma; expansion cohorts enrolling.
- Virtual analyst/investor event on June 27, 2022 to announce new target.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022007848/0000950170-22-007848-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1812364/000095017022007848/rlay-20220505.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-007848

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer